{"id":733564,"date":"2025-02-26T12:34:01","date_gmt":"2025-02-26T12:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=733564"},"modified":"2025-02-26T12:34:01","modified_gmt":"2025-02-26T12:34:01","slug":"smallcaps-under-2-on-the-move-envb-onvo-trnr-prso-pnpnv-gaining-momentum","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/smallcaps-under-2-on-the-move-envb-onvo-trnr-prso-pnpnv-gaining-momentum_733564.html","title":{"rendered":"Small-Caps Under $2 on the Move: ENVB, ONVO, TRNR, PRSO, PNPN.V Gaining Momentum"},"content":{"rendered":"
\"Small-Caps<\/a><\/div>\n

Enveric Biosciences (NASDAQ: ENVB)<\/strong> Secures Patent for EVM401 Series, Advancing Neuropsychiatric Treatments Small-cap biotech stocks continue to push boundaries, with Enveric Biosciences (NASDAQ: ENVB)<\/strong> securing U.S. Patent No. 12,195,439<\/strong> for its EVM401 Series<\/strong>, a novel class of non-hallucinogenic mescaline derivatives<\/strong> designed for addiction and neuropsychiatric disorders<\/strong>. This milestone solidifies Enveric’s standing in the neuroplastogen therapeutics<\/strong> sector, a rapidly emerging field within mental health treatment. The EVM401 compounds<\/strong> exhibit unique brain receptor modulation, potentially offering new alternatives for patients<\/strong> with limited therapeutic options.<\/p>\n

Organovo (NASDAQ: ONVO) Strikes Deal with Eli Lilly, Highlighting Small-Cap Biotech’s Appeal to Big Pharma. <\/strong>The biotech sector is buzzing as Organovo Holdings (NASDAQ: ONVO)<\/strong> secures a deal with Eli Lilly (NYSE: LLY)<\/strong> for the acquisition of its FXR program, including FXR314<\/strong>, a promising therapy for inflammatory bowel disease (IBD)<\/strong>. This transaction underscores the growing trend of big pharma acquiring small-cap biotech innovations<\/strong>, with Organovo’s proprietary 3D human tissue technology<\/strong> standing out as a major breakthrough. The deal includes upfront and milestone-based payments<\/strong>, securing FXR314’s advancement into Phase 2 trials<\/strong>.<\/p>\n

Interactive Strength (NASDAQ: TRNR) Unveils Acquisition Raising Guidence to $50M in 2025 Revenue. Interactive Strength Inc. (NASDAQ: TRNR)<\/strong>, the company behind CLMBR and FORME fitness brands<\/strong>, is proactively engaging shareholders by launching an FAQ section<\/strong> addressing its recent acquisition and $50M pro forma 2025 revenue guidance<\/strong>. TRNR is also ramping up efforts to combat potential illegal short-selling<\/strong> and provide frequent updates on operational developments<\/strong>. This move aligns with a broader trend of small-cap fitness and wellness companies scaling operations<\/strong> while navigating market manipulation concerns<\/strong>.<\/p>\n

Peraso Inc. (NASDAQ: PRSO) Pioneering the 60 GHz mmWave Revolution in 5G & Military Defense <\/strong>is emerging as a key player in the mmWave semiconductor industry<\/strong>, specializing in high-speed, low-latency connectivity<\/strong> for AI, military defense, and telecommunications<\/strong>. As the only publicly traded pure-play mmWave company<\/strong>, Peraso’s fully integrated 60 GHz technology<\/strong> is enabling next-gen applications<\/strong> in autonomous drones, 5G infrastructure, and secure military communications<\/strong>. With the rising demand for AI-driven networks<\/strong>, Peraso’s innovative solutions<\/strong> are positioned to reshape global connectivity<\/strong>.<\/p>\n

Power Metallic Mines, Inc. (TSXV: PNPN) (OTCQB: PNPNF) TSX’s #1 Miner Expands Amid Strong Investor Demand. Power Metallic Mines, Inc.<\/strong>, formerly Power Nickel<\/strong>, has increased its private placement to C$50 million<\/strong>, up from its originally planned C$40 million<\/strong>, due to overwhelming investor interest<\/strong>. The funding includes C$40 million in Quebec flow-through shares<\/strong>, reinforcing the company’s position as a leader in critical minerals for battery technology and renewable energy<\/strong>. As one of the TSX Venture 50’s top-performing mining stocks<\/strong>, Power Metallic Mines is well-positioned to capitalize on the global shift to energy metals<\/strong>. TSX Venture 50<\/a><\/p>\n

These small-cap stocks under $2<\/strong> are making headline-worthy moves<\/strong>, showcasing breakthrough technologies, strategic acquisitions, and strong investor backing<\/strong> across biotech, AI, and mining<\/strong>. With growing market traction, these companies are ones to watch in 2025 and beyond<\/strong>.<\/p>\n

 <\/p>\n

 <\/p>\n

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> The Street Reports<\/a>
Contact Person:<\/strong> Editor
Email:<\/strong> Send Email<\/a>
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.thestreetreports.com<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Enveric Biosciences (NASDAQ: ENVB) Secures Patent for EVM401 Series, Advancing Neuropsychiatric Treatments Small-cap biotech stocks continue to push boundaries, with Enveric Biosciences (NASDAQ: ENVB) securing U.S. Patent No. 12,195,439 for its EVM401 Series, a novel class of non-hallucinogenic mescaline derivatives … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,425,426,412,404],"tags":[],"class_list":["post-733564","post","type-post","status-publish","format-standard","hentry","category-Business","category-Finance","category-Financial-Market","category-News-Current-Affairs","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/733564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=733564"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/733564\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=733564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=733564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=733564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}